FDA Achieves Historically Low Eight-Month Median Drug Review Time In 2017
Median review times for US agency's drug center were 10 months from 2011 to 2013, and 11 months from 2015 to 2016.
You may also be interested in...
Inundated with high-priority applications last year, US FDA's CMC reviewers struggled with seemingly thrown-together review packages, moving-target manufacturing processes and not-on-the-same-page contract manufacturers.
The agency's Dec. 21 approval of Giapreza became novel drug No. 46 of 2017, topping the 2015 mark of 45.
The latest drug development news and highlights from our FDA Performance Tracker.